Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

Seasonal Influenza DNA vaccine

VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.

BIOLOGICAL

TIV

2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)

Trial Locations (5)

30322

Emory Children's Center, Atlanta

37232

Vanderbilt University, Nashville

45229

The Gamble Program for Clinical Studies, Cincinnati Children's Hospital Medical Center, Cincinnati

63104

Saint Louis University - Doisy Research Center, St Louis

03756

Dartmouth Hitchcock Medical Center, Lebanon

All Listed Sponsors
collaborator

The Emmes Company, LLC

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01609998 - Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents | Biotech Hunter | Biotech Hunter